Comprehensive Chikungunya Detection Solutions: ELISA Kits for Research & Diagnostics

Chikungunya fever is an acute infectious disease caused by the Chikungunya virus (CHIKV), transmitted by Aedes mosquitoes, characterized by fever, rash, and joint pain. The outbreak of chikungunya fever was first confirmed in Tanzania in 1952, and the virus was isolated in 1956. Local transmission has been reported in 119 countries and regions worldwide, with large-scale outbreaks and sporadic cases mainly occurring in the Americas, Asia, and Africa, with occasional smaller outbreaks in Europe. In recent years, it has caused a large-scale epidemic in the Indian Ocean region. The high sensitivity and rapid diagnosis of dengue fever using quantitative ELISA kits meets this demand by detecting viral markers in the early stages of infection, even before severe symptoms occur.

Figure 1. Chikungunya. (Couderc, Thérèse, et al. 2015)

Clinical Manifestation

The characteristic of chikungunya fever is sudden fever, often accompanied by severe joint pain. Joint pain usually makes people weak, usually lasting for a few days, but it can also last for a long time, such as weeks, months, or even years. Other symptoms include joint swelling, muscle pain, headache, nausea, fatigue, and rash. Due to these symptoms being similar to those of other infections such as dengue fever and Zika virus infection, cases may be misdiagnosed. In the absence of obvious joint pain, the symptoms of infected individuals are usually mild and the infection may not be recognized. Most patients fully recover from infection; But there are occasional reports of complications related to the eyes, heart, and nervous system caused by chikungunya virus infection. Patients with extreme age ranges have a higher risk of severe illness, including newborns who have been infected by their mothers during childbirth or bitten by infected mosquitoes within a few weeks after birth, as well as elderly people with underlying diseases. Severely ill patients require hospitalization due to the risk of organ damage and death.

Vaccine Development

At present, there is no vaccine or specific antiviral treatment for chikungunya fever, and symptomatic supportive treatment is mainly adopted. Patients with high fever should use physical cooling and avoid using aspirin. People with severe joint pain can use anti-inflammatory and analgesic drugs such as ibuprofen, naproxen, acetaminophen, etc. The treatment of meningoencephalitis mainly aims to prevent cerebral edema, and drugs such as mannitol and furosemide can be used to reduce intracranial pressure. This disease is self limiting and generally has a good prognosis. On November 9, 2023, it was announced that the world's first chikungunya fever vaccine, Lxcig, has been approved for use in individuals aged 18 and above. This vaccine was developed by the French biotechnology company Valneva. Chikungunya fever is transmitted by mosquito bites, and patients may experience symptoms such as fever, muscle pain, and joint pain.

Methods of Chikungunya Detection

Summary

The ELISA kit is a robust and reliable solution for detecting and monitoring chikungunya virus infection. Their wide availability, cost-effectiveness, and high accuracy make them indispensable tools in clinical diagnosis and vaccine development. As the global burden of arbovirus diseases continues to rise, the continuous improvement and accessibility of these diagnostic tools will play a key role in controlling the epidemic and improving patient outcomes.

ELISA Kits